Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas
- Status
- RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Dabrafenib
Related studies linked through entity extraction aliases.
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.
- Status
- RECRUITING
- Phase
- PHASE2
Pediatric Long-Term Follow-up and Rollover Study
- Status
- RECRUITING
- Phase
- PHASE4
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).
- Status
- COMPLETED
- Phase
- PHASE3